These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 25876877)
1. The ErbB3-binding protein EBP1 modulates lapatinib sensitivity in prostate cancer cells. Awasthi S; Ezelle H; Hassel BA; Hamburger AW Mol Cell Biochem; 2015 Jul; 405(1-2):177-86. PubMed ID: 25876877 [TBL] [Abstract][Full Text] [Related]
2. EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance. Zhang Y; Linn D; Liu Z; Melamed J; Tavora F; Young CY; Burger AM; Hamburger AW Mol Cancer Ther; 2008 Oct; 7(10):3176-86. PubMed ID: 18852121 [TBL] [Abstract][Full Text] [Related]
3. The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells. Zhang Y; Wang XW; Jelovac D; Nakanishi T; Yu MH; Akinmade D; Goloubeva O; Ross DD; Brodie A; Hamburger AW Proc Natl Acad Sci U S A; 2005 Jul; 102(28):9890-5. PubMed ID: 15994225 [TBL] [Abstract][Full Text] [Related]
4. Specificity and heregulin regulation of Ebp1 (ErbB3 binding protein 1) mediated repression of androgen receptor signalling. Zhang Y; Hamburger AW Br J Cancer; 2005 Jan; 92(1):140-6. PubMed ID: 15583694 [TBL] [Abstract][Full Text] [Related]
5. Repression of androgen receptor mediated transcription by the ErbB-3 binding protein, Ebp1. Zhang Y; Fondell JD; Wang Q; Xia X; Cheng A; Lu ML; Hamburger AW Oncogene; 2002 Aug; 21(36):5609-18. PubMed ID: 12165860 [TBL] [Abstract][Full Text] [Related]
6. Lapatinib-resistant cancer cells possessing epithelial cancer stem cell properties develop sensitivity during sphere formation by activation of the ErbB/AKT/cyclin D2 pathway. Ohnishi Y; Yasui H; Kakudo K; Nozaki M Oncol Rep; 2016 Nov; 36(5):3058-3064. PubMed ID: 27633099 [TBL] [Abstract][Full Text] [Related]
7. The ErbB3 binding protein EBP1 regulates ErbB2 protein levels and tamoxifen sensitivity in breast cancer cells. Lu Y; Zhou H; Chen W; Zhang Y; Hamburger AW Breast Cancer Res Treat; 2011 Feb; 126(1):27-36. PubMed ID: 20379846 [TBL] [Abstract][Full Text] [Related]
8. Heregulin negatively regulates transcription of ErbB2/3 receptors via an AKT-mediated pathway. Awasthi S; Hamburger AW J Cell Physiol; 2014 Nov; 229(11):1831-41. PubMed ID: 24692179 [TBL] [Abstract][Full Text] [Related]
9. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells. Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492 [TBL] [Abstract][Full Text] [Related]
10. EBP1 inhibits translation of androgen receptor mRNA in castration resistant prostate cancer cells. Zhou H; Zhang Y; Hamburger AW Anticancer Res; 2011 Oct; 31(10):3129-35. PubMed ID: 21965718 [TBL] [Abstract][Full Text] [Related]
11. Post-transcriptional regulation of androgen receptor mRNA by an ErbB3 binding protein 1 in prostate cancer. Zhou H; Mazan-Mamczarz K; Martindale JL; Barker A; Liu Z; Gorospe M; Leedman PJ; Gartenhaus RB; Hamburger AW; Zhang Y Nucleic Acids Res; 2010 Jun; 38(11):3619-31. PubMed ID: 20159994 [TBL] [Abstract][Full Text] [Related]
12. EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells. Grøvdal LM; Kim J; Holst MR; Knudsen SL; Grandal MV; van Deurs B Cell Signal; 2012 Jan; 24(1):296-301. PubMed ID: 21951604 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of heregulin mediated MCF-7 breast cancer cell growth by the ErbB3 binding protein EBP1. Zhang Y; Akinmade D; Hamburger AW Cancer Lett; 2008 Jul; 265(2):298-306. PubMed ID: 18355957 [TBL] [Abstract][Full Text] [Related]
14. ErbB3-binding protein EBP1 decreases ErbB2 levels via a transcriptional mechanism. Ghosh A; Awasthi S; Hamburger AW Oncol Rep; 2013 Mar; 29(3):1161-6. PubMed ID: 23242156 [TBL] [Abstract][Full Text] [Related]
15. ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor. Juliachs M; Castillo-Ávila W; Vidal A; Piulats JM; Garcia Del Muro X; Condom E; Hernández-Losa J; Teixidó C; Pandiella A; Graupera M; Casanovas O; Germà JR; Villanueva A; Viñals F Int J Cancer; 2013 Jul; 133(1):235-46. PubMed ID: 23292912 [TBL] [Abstract][Full Text] [Related]
16. The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells. Lyu H; Yang XH; Edgerton SM; Thor AD; Wu X; He Z; Liu B Oncotarget; 2016 Jan; 7(3):2921-35. PubMed ID: 26621843 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma. Mukohara T; Civiello G; Johnson BE; Janne PA Oncology; 2005; 68(4-6):500-10. PubMed ID: 16020981 [TBL] [Abstract][Full Text] [Related]
18. The expression and prognostic role of EBP1 and relationship with AR in HER2+ breast cancer. Liu J; Xu C; Xu D; Cao L; Xue H; Meng Q; Niu Y Virchows Arch; 2020 Aug; 477(2):279-289. PubMed ID: 32086588 [TBL] [Abstract][Full Text] [Related]
19. Regulation of tamoxifen sensitivity by a PAK1-EBP1 signalling pathway in breast cancer. Ghosh A; Awasthi S; Peterson JR; Hamburger AW Br J Cancer; 2013 Feb; 108(3):557-63. PubMed ID: 23361053 [TBL] [Abstract][Full Text] [Related]
20. The role of ErbB3 and its binding partners in breast cancer progression and resistance to hormone and tyrosine kinase directed therapies. Hamburger AW J Mammary Gland Biol Neoplasia; 2008 Jun; 13(2):225-33. PubMed ID: 18425425 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]